Drug delivery and pharmacokinetics II

Thematic Poster Session
Chairs: E. Derom (Gent, Belgium), I. M. Adcock (London, United Kingdom)

The pharmacokinetics of inhaled NVA237 in COPD patients G. Kaiser, R. Sechaud, D. Renard, L. Zhang-Auberson, S. de la Motte, A. Drollmann (Basel, Switzerland; Munich, Germany)
Comparison of pulmonary and systemic absoption of two HFA formulations of salmeterol in healthy subjects N. Morde, S. Chandran, C. J. Rebello, R. Jadhav, K. Iyer, M. Garg, R. Naidu, S. Chachad, G. Malhotra, A. Lulla, S. Purandare (Mumbai, India)
Pharmacokinetic and pharmacodinamic effect of AeroChamber Plus spacer on the Extrafine beclometasone dipropionate plus formoterol combination (200/6 µg) S. Collarini, F. Mariotti, D. Acerbi, E. Vets (Parma, Italy; Antwerpen, Belgium)
Dose linearity of beclometasone dipropionate (BDP) in a pMDI BDP plus formoterol fixed combination G. Poli, S. Collarini, D. Acerbi, M. Fantini, F. Usberti, M. De Decker (Parma, Italy; Antwerpen, Belgium)
Dose- and exposure response analysis of glycopyrrolate (GP) metered dose inhaler (MDI) to support optimal dosing in patients with COPD for combination product development C. Reisner, C. Orevillo, E. St. Rose, H. Granko, C. Jomphe, M. Beliveau, J. F. Marier (Redwood City, St. Louis, United States Of America)
Dose- and exposure-response modeling to support development of formoterol fumarate (FF) metered dose inhaler (MDI) for COPD C. Orevillo, E. St. Rose, J. F. Marier, F. Ezzet, T. Fischer, C. Reisner (Redwood City, St. Louis, United States Of America)
Therapeutic equivalence of beclomethasone dipropionate/formoterol administered via NEXTTM DPI with beclomethasone dipropionate/formoterol administered via HFA pMDI in adult asthmatic patients F. Zuccaro, F. Sergio, S. Petruzzelli, D. Singh (Parma, Italy; Manchester, United Kingdom)
Comparison of HFA fluticasone-formoterol combination pressurized meter dose inhaler (pMDI) and HFA budesonide-formoterol combination pMDI in patients with moderate to severe persistent asthma J. Gogtay, A. Balki, S. Dalal, A. Singh, S. Bardapurkar, S. Balamurugan, B. Singh, R. Mehta, S. Kant, S. Bhargava, B. Trivedi, A. Arya, S. Papinwar, S. Chandratre, B. Mutha, K. Poddar, A. Vaidya, S. Talele (Mumbai, Nagpur, Vadodara, Jaipur, Aurangabad, Chennai, Lucknow, Indore, Nashik, Delhi, Kolkatta, India)
Evaluation of the usability, confidence and satisfaction of a novel dry powder inhaler for obstructive airway disease (OAD) J. Gogtay, P. Niphadkar, S. Rajan, I. Bubna, S. Srisvastava, M. Repal, P. Londhe, S. Jadhav (Mumbai, India)
A breath-actuated jet nebulizer (BAN) has dosimetric capability for a suspension formulation based on differing volume fill of medication as well as run time J. Malpass, M. Nagel, C. Doyle, R. Ali, V. Avvakoumova, J. Mitchell (London, Canada)
Different inhalation volumes do not impact on the aerodynamics of aclidinium bromide delivered using the Genuair® inhaler K. Block, B. Fyrnys (Bad Homburg, Germany)
Excretion and metabolism of [14C]aclidinium bromide administered intravenously in healthy subjects S. Flach, J. Jansat, J. Ho, E. Garcia Gil, C. Caracta, S. Ortiz (Madison, Jersey City, United States Of America; Barcelona, Spain)
Roflumilast and sildenafil in healthy male volunteers: Single-dose pharmacokinetic interactions, safety and tolerability A. Hünnemeyer, N. Nassr, A. Manegold, R. Fux, G. M. Böhmer, G. Lahu, C. Gleiter (Konstanz, Germany)
Comparative lung bioavailability of fluticasone/salmeterol via breath actuated vortex spacer and conventional plastic spacers A. Nair, L. McKinlay, P. Williamson, P. Short, P. Burns, B. Lipworth (United Kingdom)
Highly effective delivery of medication is possible in home use with improved breath-actuated nebulizer (BAN) driven by home compressor J. Malpass, M. Nagel, V. Avvakoumova, H. MacKay, C. Doyle, J. Mitchell (London, Canada)
Relationship between the inhaled and pulmonary absorbed dose of budesonide and mometasone furoate: A study in the isolated perfused rat lung P. Ewing, S. Eirefelt, S. Edsbäcker, A. Miller-Larsson (Lund, Sweden)
Transition to extra-fine formulation of inhaled beclomethasone/formoterol improves clinical and functional parameters in controlled and partly controlled asthmatics T. Kralimarkova, D. Petrova, Y. Ivanov, D. Popov, C. Odzhakova, Y. Ilieva, G. Ivanova, P. Yakovliev, T. Lazarova, A. Buchvarova, K. Kostov, O. Georgiev, V. Hodzhev, M. Staevska, P. Nikolova, V. Dimitrov, T. Popov (Pleven, Sofia, Varna, Plovdiv, Bulgaria)
Comparison of the adherence of the oral pharmacokinetically enhanced formulation of amoxicillin/clavulanic acid 2,000/125 mg twice daily with that of the standard formulation of amoxicillin/clavulanic acid 500/125 mg thrice daily C. Llor, N. Sierra, S. Hernández, C. Bayona, A. Moragas, M. Miravitlles (Tarragona, Valls, Barcelona, Spain)
Systemic exposure and topical efficacy for inhaled fluticasone propionate (FP) in asthmatics R. Mehta, A. Moore, M. Beerahee, P. Daley-Yates (Durham, United States Of America; Stockley Park West, Uxbridge, Stevenage, United Kingdom)
Multiple ascending subcutaneous (SC) dose study of MEDI-563: Pharmacokinetics and immune response in adult asthmatics F. Jin, W. White, D. Gossage, G. Geba, N. Molfino (Gaithersburg, United States Of America)